View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, April 23 (HealthDay News) -- In type 2 diabetes patients who have inadequate glycemic control on metformin therapy, liraglutide injections are well tolerated and are more effective than oral sitagliptin in reducing HbA1C, according to a study in the April 24 issue of The Lancet.
Richard E. Pratley, M.D., of the University of Vermont College of Medicine in Burlington, and colleagues conducted a 26-week parallel-group, open-label trial in which they randomly assigned participants with type 2 diabetes to receive 1.2 or 1.8 mg subcutaneous liraglutide or 100 mg oral sitagliptin once daily. Enrolled patients had all been on metformin at a dose of at least 1500 mg/day for at least three months with suboptimal glycemic control.
The researchers found that liraglutide reduced HbA1C by 1.50 and 1.24 percent, respectively, for the 1.8 and 1.2 mg dosages; sitagliptin reduced it by 0.90 percent. The estimated mean treatment difference for liraglutide versus sitagliptin was −0.60 percent for the 1.8 mg dose and −0.34 percent for the 1.2 mg dose. Both the liraglutide and sitagliptin groups had about a 5 percent incidence of minor hypoglycemia; nausea was more common in the liraglutide group (27 percent on 1.8 mg; 21 percent on 1.2 mg.) than in the sitagliptin group (5 percent).
"Even though Pratley and colleagues recorded superior treatment satisfaction with 1.8 mg liraglutide than with sitagliptin, the gastrointestinal tolerance profile is better with sitagliptin than with liraglutide, and one pill of sitagliptin daily might be judged as easier to administer than one subcutaneous injection of liraglutide daily. The increased cost of liraglutide should be compared with the benefit provided by improved glucose control and weight reduction," write the authors of an accompanying editorial.
The study was funded by Novo Nordisk; several authors disclosed financial ties to Novo Nordisk and other companies.
Full Text (subscription or payment may be required)
Comment (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top